Tremella polysaccharide with effect of preventing and treating colitis and preparation method thereof

By preparing Tremella polysaccharides with specific structures, the problems of low extraction efficiency and low purity in the prior art are solved, and the effects of efficient prevention and treatment of colitis and improving gastrointestinal dysfunction are achieved, which is suitable for industrial production.

CN120424244APending Publication Date: 2025-08-05SICHUAN EDIBLE FUNGI RES INST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510590805.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-09-28
Filing Date
2025-05-08
Publication Date
2025-08-05

AI Technical Summary

Technical Problem

In the prior art, the active ingredient extraction efficiency and low purity of Tremella polysaccharides lead to poor treatment effect of colitis and the long-term use of common drugs has side effects.

Method used

A Tremella polysaccharide with a specific structure is prepared. Through water soaking, enzymatic decomposition, ion exchange and gel chromatography, a Tremella polysaccharide with a number average molecular weight of 1kDa-250kDa is obtained, with a content of no less than 80%. Each monosaccharide is 40-60%, glucose 20-30%, galactose 0.1-10%, xylose 10-20%, fucose 10-20%, and is used to prepare a pharmaceutical composition.

Benefits of technology

It has achieved efficient prevention and treatment of colitis, reduced the dosage of colitis, improved bioavailability, and improved gastrointestinal dysfunction caused by digestive system diseases. It has good immune regulation and intestinal barrier maintenance functions, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120424244A_ABST
    Figure CN120424244A_ABST
Patent Text Reader

Abstract

The tremella polysaccharide has a structure as shown in a formula I. The tremella polysaccharide maintains an intestinal barrier by regulating immunity, recovering intestinal microbiota and microbial metabolism and maintaining the integrity of intestinal cells so as to realize the prevention and treatment of colitis. # imgabs0 # has the advantages of being capable of reducing the use dosage of colitis and the total content of DAI, good in effectiveness, high in bioavailability, good in patient compliance and the like, and meanwhile has a good improvement effect on gastrointestinal dysfunction caused by digestive system diseases, and # imgabs0 # imgabs0 # imgabs0 # imgabs0 # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicine, and particularly relates to a tremella polysaccharide with the effect of preventing and treating colitis and a preparation method thereof. Background Art

[0002] Colitis refers to an inflammatory lesion of the colon caused by various reasons. The clinical manifestations of colitis include diarrhea, abdominal pain, mucus and bloody stools, tenesmus, and even constipation, and inability to defecate for several days; it is often accompanied by weight loss and fatigue, and the disease often recurs. Studies have shown that the onset of colitis is related to the integrity and permeability of the intestinal barrier, and nonspecific inflammation runs through the entire course of colitis. Inhibiting inflammation and enhancing gastrointestinal barrier function have become key strategies for the clinical prevention and treatment of colitis. The common method of treating colitis is to give drugs such as aminosalicylic acid, glucocorticoids, and immunosuppressants, which can only solve short-term symptoms and have many side effects with long-term use.

[0003] Tremella polysaccharides are the main active ingredients of Tremella fuciformis (Tremella) and include acidic polysaccharides, neutral polysaccharides, neutral heteropolysaccharides, acidic oligosaccharides, cell wall polysaccharides, and extracellular polysaccharides. They have cardiotonic, anti-aging, anti-thrombotic, anti-tumor, immune-enhancing, and chloasma-removing properties, and are widely used in food, health products, and cosmetics. Tremella polysaccharides have been shown to be effective in preventing colitis, but the extraction efficiency and purity of the active ingredients are low, and the required dosage is high. There is a need to prepare Tremella polysaccharides that can better prevent colitis. Summary of the Invention

[0004] The object of the present invention is to provide a Tremella polysaccharide having the efficacy of preventing and treating colitis, which has a structure of formula I,

[0005]

[0006] In the preferred technical solution of the present invention, in the structure of formula I, the main chain structure is formed by repeating →3)-α-D-mannose-(1→) and →2,3)-α-D-6-methoxyglucuronic acid-(1→) units connected to each other; branch one is composed of β-D-glucuronic acid-(1→); branch two is composed of α-L-fucose connected to β-D-xylose-(1→) through a (1→2) bond; the branch is connected to the main chain through the O-2 position of the sugar residue →2,3)-α-D-6-methoxyglucuronic acid-(1→ in the main chain; n represents the number of sugar groups connected in the sugar chain, and n is greater than 10.

[0007] In the preferred technical solution of the present invention, the number average molecular weight of the Tremella polysaccharide is 1kDa-250kDa, preferably 1kDa-100kDa, more preferably 1kDa-50kDa, and even more preferably 1kDa-10kDa.

[0008] In the preferred technical solution of the present invention, the polysaccharide content in Tremella polysaccharide is not less than 80%, preferably not less than 90%.

[0009] In the preferred technical solution of the present invention, the monosaccharide distribution in Tremella polysaccharide is 40-60% mannose, 20-30% glucose, 0.1-10% galactose, 10-20% xylose and 10-20% fucose.

[0010] In the preferred technical solution of the present invention, the distribution of monosaccharides in Tremella fuciformis polysaccharide is: mannose 50.52%, glucuronic acid 23.12%, galactose 0.97%, xylose 11.95%, and fucose 13.44%.

[0011] In a preferred technical solution of the present invention, the preparation method of Tremella polysaccharide comprises the following steps:

[0012] (1) soaking Tremella fuciformis in water and sieving it, centrifuging the sieved liquid, and collecting the residue;

[0013] (2) adding water to the residue from step (1) for extraction, collecting the filtrate, adding ethanol to the filtrate, and collecting the solid phase by alcohol precipitation;

[0014] (3) adding protease to the solid phase of step (2) for enzymatic hydrolysis, and collecting the enzymatic hydrolysis solution;

[0015] (4) adding chloroform / n-butanol to the enzymatic hydrolyzate of step (3), mixing, centrifuging, and collecting the supernatant;

[0016] (5) adding petroleum ether to the supernatant of step (4), mixing, centrifuging, and collecting the supernatant; then adding ethanol, precipitating with alcohol, centrifuging, and collecting the precipitate to obtain crude polysaccharide;

[0017] (6) dissolving the crude polysaccharide in step (5) in water, centrifuging, taking the supernatant, and purifying it through an ion exchange column; collecting the eluate, concentrating it, and desalting it to obtain the purified polysaccharide;

[0018] (7) The polysaccharide purified in step (6) is dissolved in water, centrifuged, the supernatant is collected, and the supernatant is separated and purified by gel chromatography column, and the eluate is collected and concentrated to obtain Tremella polysaccharide.

[0019] In the preferred technical solution of the present invention, in the step (1), water is added to the crushed dry white fungus at a mass volume ratio of 1:50-100 and the mixture is soaked for 12-24 hours, the mixture is sieved through a 100-mesh sieve to obtain a residue 1 and a sieved liquid, the sieved liquid is centrifuged to obtain a residue 2, the residue 1 and the residue 2 are combined, and then water is added to the mixture at a mass volume ratio of 1:50-100 and the mixture is soaked for 12-24 hours, and the mixture is sieved through a 100-mesh sieve to obtain a residue 3.

[0020] In the preferred technical solution of the present invention, in step (1), the crushed dry white fungus has a mesh size of 80-100.

[0021] In the preferred technical solution of the present invention, in step (1), the centrifugation conditions are 5000-10000g*10-30min, preferably 5000-8000g*10-20min.

[0022] In the preferred technical solution of the present invention, in the step (2), water is added to the residue 3 of step (1) at a mass volume ratio of 1:50-100, and the mixture is extracted at 70-90°C for 1-5 hours. The extract is centrifuged to obtain filtrate 1 and a precipitate. Water is added to the precipitate at a mass volume ratio of 1:50-100, and the mixture is extracted at 70-90°C for 1-5 hours. The extract is centrifuged to obtain filtrate 2. After combining filtrate 1 and filtrate 2, 4-10 times the volume of anhydrous ethanol is added, and the mixture is precipitated with alcohol for 12-20 hours until the precipitate no longer precipitates. The precipitate is centrifuged to obtain a solid phase and a liquid phase.

[0023] In the preferred technical solution of the present invention, in step (2), the centrifugation conditions are 5000-10000g*5-30min, preferably 8000-10000g*10-20min.

[0024] In the preferred technical solution of the present invention, in step (3), 1-8% papain solution is added to the solid phase of step (2) at a mass volume ratio of 1:50-100, and enzymatic hydrolysis is carried out at 60-70°C for 12-24h to obtain an enzymatic hydrolyzate.

[0025] In the preferred technical solution of the present invention, in step (4), a chloroform / n-butanol mixed solution is added to the enzymatic hydrolyzate of step (3) at a volume ratio of 1:1-10, the mixture is thoroughly mixed and then centrifuged to collect the supernatant.

[0026] In the preferred technical solution of the present invention, in step (4), the volume ratio of chloroform to n-butanol in the chloroform / n-butanol mixed solution is 1-6:1, preferably 1-4:1.

[0027] In the preferred technical solution of the present invention, in step (4), the centrifugation conditions are 1500-3000g*10-30min, preferably 1500-2000g*10-20min.

[0028] In the preferred technical solution of the present invention, in the step (5), petroleum ether accounting for 1-10% of the volume of the supernatant is added to the supernatant of step (4), the mixture is fully mixed and then centrifuged. After the supernatant is collected, 4-10 times the volume of anhydrous ethanol is added, the mixture is precipitated with alcohol for 12-24 hours, centrifuged, and the precipitate is collected to obtain crude polysaccharide.

[0029] In the preferred technical solution of the present invention, in step (5), the centrifugation conditions are 1500-3000g*10-30min, preferably 1500-2000g*10-20min.

[0030] In the preferred technical solution of the present invention, in step (6), the crude polysaccharide of step (5) is dissolved in water to prepare a crude polysaccharide mother liquor of 10-20 mg / mL, centrifuged, the supernatant is passed through an ion exchange column, gradient elution is performed, the eluate is collected, and the eluate is concentrated by rotary evaporation to 1 / 5-1 / 3 of the original volume, dialyzed (3000 Da) for 48-72 hours, and dried to obtain the purified polysaccharide.

[0031] In the preferred technical solution of the present invention, in step (6), the centrifugation conditions are 10000-15000g*10-30min, preferably 10000-12000g*10-20min.

[0032] In the preferred technical solution of the present invention, in step (6), the ion exchange column filler is selected from any one of DEAE cellulose, DEAE dextran, DEAE agarose or a combination thereof.

[0033] In the preferred technical solution of the present invention, in step (6), the flow rate of the supernatant through the ion exchange column is 1-10 mL / min, preferably 4-8 mL / min.

[0034] In the preferred technical solution of the present invention, in step (6), the step of gradient elution and collecting the eluate is: first eluting with pure water until the OD value of the polysaccharide content in the eluate is less than 0.05, then replacing with 0.1MNaCl solution and eluting until the OD value of the polysaccharide content in the eluate is less than 0.05, collecting the 0.1MNaCl eluate, concentrating it by rotary evaporation to 1 / 5 of the original volume, and dialyzing it with a 3000Da dialysis bag for 48 to 72 hours to obtain the purified polysaccharide.

[0035] In the preferred technical solution of the present invention, in the step (7), the polysaccharide purified in the step (6) is dissolved in water to prepare a 10-20 mg / mL polysaccharide mother liquor, centrifuged, and the supernatant is passed through a gel chromatography column, eluted with water, and the eluate is collected and concentrated by rotary evaporation to 1 / 5-1 / 3 of the original volume to obtain Tremella polysaccharide.

[0036] In the preferred technical solution of the present invention, in step (7), the centrifugation conditions are 10000-15000g*10-20min, preferably 10000-12000g*10-20min.

[0037] In the preferred technical solution of the present invention, in step (7), 1-5 column volumes of water are used for elution, preferably 1.5-3 column volumes of water are used for elution.

[0038] In the preferred technical solution of the present invention, in step (7), the flow rate of the supernatant through the gel chromatography column is 1-10 mL / min, preferably 1-6 mL / min.

[0039] In the preferred technical solution of the present invention, in step (7), the gel chromatography column filler is any one of Superdex 75, Superdex 200, Superdex 30 or a combination thereof.

[0040] Another object of the present invention is to provide a method for preparing the Tremella polysaccharide having the effect of preventing and treating colitis. The Tremella polysaccharide has a structure of formula I,

[0041]

[0042] The preparation method comprises the following steps:

[0043] (1) soaking Tremella fuciformis in water and sieving it, centrifuging the sieved liquid, and collecting the residue;

[0044] (2) adding water to the residue from step (1) for extraction, collecting the filtrate, adding ethanol to the filtrate, and collecting the solid phase by alcohol precipitation;

[0045] (3) adding protease to the solid phase of step (2) for enzymatic hydrolysis, and collecting the enzymatic hydrolysis solution;

[0046] (4) adding chloroform / n-butanol to the enzymatic hydrolyzate of step (3), mixing, centrifuging, and collecting the supernatant;

[0047] (5) adding petroleum ether to the supernatant of step (4), mixing, centrifuging, and collecting the supernatant; then adding ethanol, precipitating with alcohol, centrifuging, and collecting the precipitate to obtain crude polysaccharide;

[0048] (6) dissolving the crude polysaccharide in step (5) in water, centrifuging, taking the supernatant, and purifying it through an ion exchange column; collecting the eluate, concentrating it, and desalting it to obtain the purified polysaccharide;

[0049] (7) The polysaccharide purified in step (6) is dissolved in water, centrifuged, the supernatant is collected, and the supernatant is separated and purified by gel chromatography column, and the eluate is collected and concentrated to obtain Tremella polysaccharide.

[0050] In the preferred technical solution of the present invention, in the step (1), water is added to the crushed dry white fungus at a mass volume ratio of 1:50-100 and the mixture is soaked for 12-24 hours, the mixture is sieved through a 100-mesh sieve to obtain a residue 1 and a sieved liquid, the sieved liquid is centrifuged to obtain a residue 2, the residue 1 and the residue 2 are combined, and then water is added to the mixture at a mass volume ratio of 1:50-100 and the mixture is soaked for 12-24 hours, and the mixture is sieved through a 100-mesh sieve to obtain a residue 3.

[0051] In the preferred technical solution of the present invention, in step (1), the crushed dry white fungus has a mesh size of 80-100.

[0052] In the preferred technical solution of the present invention, in step (1), the centrifugation conditions are 5000-10000g*10-30min, preferably 5000-8000g*10-20min.

[0053] In the preferred technical solution of the present invention, in the step (2), water is added to the residue 3 of step (1) at a mass volume ratio of 1:50-100, and the mixture is extracted at 70-90°C for 1-5 hours. The extract is centrifuged to obtain filtrate 1 and a precipitate. Water is added to the precipitate at a mass volume ratio of 1:50-100, and the mixture is extracted at 70-90°C for 1-5 hours. The extract is centrifuged to obtain filtrate 2. After combining filtrate 1 and filtrate 2, 4-10 times the volume of anhydrous ethanol is added, and the mixture is precipitated with alcohol for 12-20 hours until the precipitate no longer precipitates. The precipitate is centrifuged to obtain a solid phase and a liquid phase.

[0054] In the preferred technical solution of the present invention, in step (2), the centrifugation conditions are 5000-10000g*5-30min, preferably 8000-10000g*10-20min.

[0055] In the preferred technical solution of the present invention, in step (3), 1-8% papain solution is added to the solid phase of step (2) at a mass volume ratio of 1:50-100, and enzymatic hydrolysis is carried out at 60-70°C for 12-24h to obtain an enzymatic hydrolyzate.

[0056] In the preferred technical solution of the present invention, in step (4), a chloroform / n-butanol mixed solution is added to the enzymatic hydrolyzate of step (3) at a volume ratio of 1:1-10, the mixture is thoroughly mixed and then centrifuged to collect the supernatant.

[0057] In the preferred technical solution of the present invention, in step (4), the volume ratio of chloroform to n-butanol in the chloroform / n-butanol mixed solution is 1-6:1, preferably 1-4:1.

[0058] In the preferred technical solution of the present invention, in step (4), the centrifugation conditions are 1500-3000g*10-30min, preferably 1500-2000g*10-20min.

[0059] In the preferred technical solution of the present invention, in the step (5), petroleum ether accounting for 1-10% of the volume of the supernatant is added to the supernatant of step (4), the mixture is fully mixed and then centrifuged. After the supernatant is collected, 4-10 times the volume of anhydrous ethanol is added, the mixture is precipitated with alcohol for 12-24 hours, centrifuged, and the precipitate is collected to obtain crude polysaccharide.

[0060] In the preferred technical solution of the present invention, in step (5), the centrifugation conditions are 1500-3000g*10-30min, preferably 1500-2000g*10-20min.

[0061] In the preferred technical solution of the present invention, in step (6), the crude polysaccharide of step (5) is dissolved in water to prepare a crude polysaccharide mother liquor of 10-20 mg / mL, centrifuged, the supernatant is passed through an ion exchange column, gradient elution is performed, the eluate is collected, and the eluate is concentrated by rotary evaporation to 1 / 5-1 / 3 of the original volume, dialyzed (3000 Da) for 48-72 hours, and dried to obtain the purified polysaccharide.

[0062] In the preferred technical solution of the present invention, in step (6), the centrifugation conditions are 10000-15000g*10-30min, preferably 10000-12000g*10-20min.

[0063] In the preferred technical solution of the present invention, in step (6), the ion exchange column filler is selected from any one of DEAE cellulose, DEAE dextran, DEAE agarose or a combination thereof.

[0064] In the preferred technical solution of the present invention, in step (6), the flow rate of the supernatant through the ion exchange column is 1-10 mL / min, preferably 4-8 mL / min.

[0065] In the preferred technical solution of the present invention, in step (6), the step of gradient elution and collecting the eluate is: first eluting with pure water until the OD value of the polysaccharide content in the eluate is less than 0.05, then replacing with 0.1MNaCl solution and eluting until the OD value of the polysaccharide content in the eluate is less than 0.05, collecting the 0.1MNaCl eluate, concentrating it by rotary evaporation to 1 / 5 of the original volume, and dialyzing it with a 3000Da dialysis bag for 48 to 72 hours to obtain the purified polysaccharide.

[0066] In the preferred technical solution of the present invention, in the step (7), the polysaccharide purified in the step (6) is dissolved in water to prepare a 10-20 mg / mL polysaccharide mother liquor, centrifuged, and the supernatant is passed through a gel chromatography column, eluted with water, and the eluate is collected and concentrated by rotary evaporation to 1 / 5-1 / 3 of the original volume to obtain Tremella polysaccharide.

[0067] In the preferred technical solution of the present invention, in step (7), the centrifugation conditions are 10000-15000g*10-20min, preferably 10000-12000g*10-20min.

[0068] In the preferred technical solution of the present invention, in step (7), 1-5 column volumes of water are used for elution, preferably 1.5-3 column volumes of water are used for elution.

[0069] In the preferred technical solution of the present invention, in step (7), the flow rate of the supernatant through the gel chromatography column is 1-10 mL / min, preferably 1-6 mL / min.

[0070] In the preferred technical solution of the present invention, in step (7), the gel chromatography column filler is any one of Superdex 75, Superdex 200, Superdex 30 or a combination thereof.

[0071] In the preferred technical solution of the present invention, in the structure of formula I, the main chain structure is formed by repeating →3)-α-D-mannose-(1→) and →2,3)-α-D-6-methoxyglucuronic acid-(1→) units connected to each other; branch one is composed of β-D-glucuronic acid-(1→); branch two is composed of α-L-fucose connected to β-D-xylose-(1→) through a (1→2) bond; the branch is connected to the main chain through the O-2 position of the sugar residue →2,3)-α-D-6-methoxyglucuronic acid-(1→ in the main chain; n represents the number of sugar groups connected in the sugar chain, and n is greater than 10.

[0072] In the preferred technical solution of the present invention, the number average molecular weight of the Tremella polysaccharide is 1kDa-250kDa, preferably 1kDa-100kDa, more preferably 1kDa-50kDa, and even more preferably 1kDa-10kDa.

[0073] In the preferred technical solution of the present invention, the polysaccharide content in Tremella polysaccharide is not less than 80%, preferably not less than 90%.

[0074] In the preferred technical solution of the present invention, the monosaccharide distribution in Tremella polysaccharide is 40-60% mannose, 20-30% glucose, 0.1-10% galactose, 10-20% xylose and 10-20% fucose.

[0075] In the preferred technical solution of the present invention, the distribution of monosaccharides in Tremella fuciformis polysaccharide is: mannose 50.52%, glucuronic acid 23.12%, galactose 0.97%, xylose 11.95%, and fucose 13.44%.

[0076] Another object of the present invention is to provide a pharmaceutical composition consisting of the Tremella polysaccharide of the present invention having high efficacy in preventing and treating colitis and a pharmaceutically acceptable carrier.

[0077] In the preferred technical solution of the present invention, the pharmaceutical composition can be in various dosage forms well known in the art and can be prepared using conventional formulation techniques in the art.

[0078] In a preferred technical solution of the present invention, the dosage form of the pharmaceutical composition is selected from any one of an oral preparation and an external preparation.

[0079] In a preferred technical solution of the present invention, the oral preparation is selected from any one of a solution, tablet, capsule, granule, syrup, powder, dew, effervescent, suspension, pill, dripping pill, mixture, paste, emulsion, and liniment.

[0080] In a preferred technical solution of the present invention, the external preparation is selected from any one of a gel, ointment, patch, cream, unguent, liniment, lotion, suppository, smear, gel paste, aerosol, dry powder inhaler, spray, nasal spray, and atomizer.

[0081] In the preferred technical solution of the present invention, the type of the pharmaceutically acceptable carrier or its dosage is determined according to factors such as the physicochemical properties and content of the active ingredient, the type of preparation, the dissolution and bioavailability of the preparation, and the like.

[0082] In a preferred technical solution of the present invention, the pharmaceutically acceptable carrier is selected from any one or a combination of fillers (diluents), disintegrants, binders, lubricants (glidants or anti-adhesives), dispersants, wetting agents, pH regulators (acid-base regulators), osmotic pressure regulators, pore-forming agents, solubilizers, antioxidants, antibacterial agents (bactericides), analgesics (anesthetics), suspending agents, emulsifiers, co-emulsifiers, lyoprotectants, flavoring agents, and fragrances.

[0083] In a preferred technical solution of the present invention, the filler is selected from any one or a combination of lactose, powdered sugar, dextrin, starch or its derivatives, cellulose or its derivatives, inorganic calcium salts, sorbitol, mannitol, etc., preferably, the inorganic calcium salt is selected from any one or a combination of calcium chloride, calcium sulfate, calcium phosphate, calcium hydrogen phosphate, and precipitated calcium carbonate, preferably, the cellulose derivative is selected from any one or a combination of microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose, and hydroxypropyl methyl cellulose, and preferably, the starch derivative is selected from any one or a combination of sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch, potato starch, and corn starch.

[0084] In a preferred technical solution of the present invention, the disintegrant is selected from any one or a combination of starch or its derivatives, cross-linked polyvinyl pyrrolidone, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and cross-linked sodium carboxymethyl cellulose. Preferably, the starch derivative is selected from any one or a combination of sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch, potato starch, and corn starch.

[0085] In a preferred technical solution of the present invention, the binder is selected from any one or a combination of syrup, gum arabic, gelatin, sorbitol, tragacanth, cellulose or its derivatives, gelatin slurry, starch slurry, polyvinyl pyrrolidone, preferably the cellulose derivative is selected from any one or a combination of microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, preferably the starch derivative is selected from any one or a combination of sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch, potato starch, corn starch.

[0086] In a preferred technical solution of the present invention, the lubricant is selected from any one of micropowdered silica gel, magnesium stearate, talc, colloidal silicon dioxide, aluminum hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol, and sodium lauryl sulfate, or a combination thereof.

[0087] In a preferred technical solution of the present invention, the wetting agent is selected from any one of sodium lauryl sulfate, polysorbate (Tween), water, alcohol, ester, or a combination thereof.

[0088] In a preferred technical solution of the present invention, the antioxidant is selected from any one of sodium sulfite, sodium bisulfite, sodium metabisulfite, sodium thiosulfate, vitamin C, vitamin E, butylated benzoic acid, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG), and tert-butylhydroquinone (TBHQ), or a combination thereof.

[0089] In a preferred technical solution of the present invention, the bacteriostatic agent (bactericide) is selected from any one of phenol, cresol, chlorobutanol, benzyl alcohol, or a combination thereof.

[0090] In a preferred technical solution of the present invention, the suspending agent is selected from any one of microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, syrup, glycerin, gelatin, gum arabic, tragacanth gum, sodium (potassium) alginate, and pectin, or a combination thereof.

[0091] In a preferred technical solution of the present invention, the acid-base regulator (pH regulator) is selected from any one of hydrochloric acid, sodium hydroxide, potassium hydroxide, citric acid, sodium citrate, potassium citrate, malic acid, sodium malate, potassium malate, sodium dihydrogen phosphate, disodium hydrogen phosphate, calcium hydroxide, calcium lactate, sodium lactate, sodium phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium bicarbonate, and sodium carbonate, or a combination thereof.

[0092] In a preferred technical solution of the present invention, the osmotic pressure regulator is selected from any one of sodium chloride, potassium chloride, glucose, phosphate, and citrate.

[0093] In the preferred technical solution of the present invention, the emulsifier is selected from any one of sodium stearate, potassium stearate, triethanolamine stearate, magnesium stearate, calcium stearate, sodium lauryl sulfate, sodium dodecylbenzenesulfonate, polysorbate (Tween), Span, benzyl alcohol, benzyl alcohol, tragacanth gum, gum arabic, Pluronic F-68, lecithin, and soy lecithin, or a combination thereof.

[0094] In a preferred technical solution of the present invention, the co-emulsifier is selected from any one of n-butanol, ethylene glycol, ethanol, propylene glycol, glycerol, and polyglycerol esters, or a combination thereof.

[0095] In a preferred technical solution of the present invention, the lyoprotectant is selected from any one of sucrose, lactose, galactose, glucose, trehalose, mannitol, and sorbitol, or a combination thereof.

[0096] In the preferred technical solution of the present invention, the solubilizer is selected from any one of Tween-80, Pluronic F-68, PEG, benzyl alcohol, bile salt, deoxycholate, glycerol, propylene glycol, and polyethylene glycol, or a combination thereof.

[0097] In a preferred technical solution of the present invention, the flavoring agent is selected from any one of honey, syrup, acid, alkali, essence, sweetener, or a combination thereof.

[0098] In a preferred technical solution of the present invention, the pharmaceutical composition of the present invention is combined with a pharmaceutically acceptable sustained-release preparation carrier or a controlled-release preparation carrier according to the preparation method of sustained-release preparation or controlled-release preparation in the art, such as adding a blocker coating or making it into a matrix-type preparation, to prepare it into a sustained-release preparation or a controlled-release preparation.

[0099] In a preferred technical solution of the present invention, the sustained-release preparation carrier or controlled-release preparation carrier is selected from any one of an oily admixture, a hydrophilic colloid, a water-insoluble retarder, an enteric retarder, a biodegradable retarder, or a combination thereof.

[0100] In a preferred technical solution of the present invention, the oily admixture is selected from any one of glyceryl monostearate, hydrogenated castor oil, mineral oil, polysiloxane or dimethylsiloxane, or a combination thereof.

[0101] In the preferred technical solution of the present invention, the hydrophilic colloid is selected from any one of methylcellulose (MC), sodium carboxymethylcellulose (CMC-Na), hydroxyethylcellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HMPC), polyvinyl pyrrolidone (PVP), gum arabic, tragacanth or carbopol, polyvinyl alcohol (PVA), pectin, alginate, chitosan, xanthan gum, guar gum, guar gum, gelatin, agar, and galactomannan, or a combination thereof.

[0102] In a preferred technical solution of the present invention, the water-insoluble retarder is selected from any one of ethyl cellulose (EC), cellulose acetate (CA), polyethylene, polypropylene, polysiloxane, ethylene vinyl acetate copolymer (EVA), and polymethyl methacrylate, or a combination thereof.

[0103] In the preferred technical solution of the present invention, the enteric retarder is selected from any one of cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose phthalate (HMPCP), polyvinyl alcohol phthalate (PVAP), hydroxypropylmethylcellulose acetate succinate (HPMCAS) and acrylic resin or a combination thereof.

[0104] In a preferred technical solution of the present invention, the biodegradable retarder is selected from any one of waxes, fatty acids, fatty acid esters, fatty alcohols, carnauba wax, stearic acid, glyceryl monostearate, stearyl alcohol, and cetyl alcohol, or a combination thereof.

[0105] In a preferred technical solution of the present invention, the administration method of the drug or pharmaceutical composition is selected from any one of oral administration, injection administration, mucosal administration, and skin administration.

[0106] Another object of the present invention is to provide the use of the Tremella polysaccharide of the present invention in preparing products for preventing and treating colitis.

[0107] In the preferred technical solution of the present invention, the Tremella polysaccharide prevents and treats colitis by immunomodulation and restoring intestinal microflora and microbial metabolism.

[0108] In the preferred technical solution of the present invention, the Tremella polysaccharide prevents and treats colitis by maintaining the integrity of intestinal cells to protect the intestinal barrier.

[0109] Another object of the present invention is to provide the use of the Tremella polysaccharide of the present invention in preparing a product for improving gastrointestinal dysfunction.

[0110] In the preferred technical solution of the present invention, the gastrointestinal dysfunction is gastrointestinal dysfunction caused by digestive system diseases.

[0111] In the preferred technical solution of the present invention, the digestive system disease is any one of inflammatory bowel disease (IBD), irritable bowel syndrome, alcoholic liver disease, non-alcoholic fatty liver disease, steatohepatitis, and cirrhosis, or a combination thereof.

[0112] Another object of the present invention is to provide the use of the Tremella polysaccharide of the present invention in preparing products for regulating intestinal flora and enhancing immunity.

[0113] In the preferred technical solution of the present invention, the product is selected from any one of medicines, functional foods, and special medical foods.

[0114] Unless otherwise specified, when the present invention relates to the percentage between liquids, the percentages are volume / volume percentages; when the present invention relates to the percentage between liquids and solids, the percentages are volume / weight percentages; when the present invention relates to the percentage between solids and liquids, the percentages are weight / volume percentages; and the rest are weight / weight percentages.

[0115] Unless otherwise specified, the molecular weights in the present invention are all number average molecular weights Mn.

[0116] 1. The sulfuric acid-phenol method was used to identify the content of Tremella polysaccharide. The specific operation was as follows: weigh the sample, dissolve it in water, add sulfuric acid-phenol reagent, react in the dark for 10 minutes, and measure the absorbance at 490 nm.

[0117] 2. Molecular Weight Determination of Tremella Polysaccharide: Gel exclusion chromatography columns Ohpak SB-805 HQ (300 × 8 mm) and Ohpak SB-803 HQ (300 × 8 mm) were connected in series. The column temperature was 45°C, the injection volume was 100 μL, the mobile phase was A (0.02% NaN₃, 0.1 M NaNO₃), the flow rate was 0.6 mL / min, and the elution gradient was isocratic for 75 min.

[0118] 3. Analysis of Monosaccharide Composition of Tremella Polysaccharides: Chromatographic Detection Method: Weigh an appropriate amount of polysaccharide sample into a clean chromatographic vial, add 1 ml of 2M TFA solution, and heat at 121°C for 2 hours. Purge with nitrogen and blow dry. Rinse with 99.99% methanol, blow dry again, and repeat the methanol wash 2-3 times. Dissolve in sterile water and transfer to a chromatographic vial for analysis. Monosaccharide composition was analyzed using a Thermo ICS 5000+ ion chromatography system (ICS 5000+, Thermo Fisher Scientific, USA) using an electrochemical detector.

[0119] 4. Molecular structure characterization of Tremella fuciformis polysaccharides: A Nicolet iZ-10 Fourier transform infrared spectrometer was used to scan and analyze the infrared spectral characteristics. Based on the properties of the polysaccharide, polysaccharide methylation combined with GC-MS analysis was further used to identify the interglycosidic bonds between monosaccharide residues. Then, one-dimensional and two-dimensional nuclear magnetic resonance (NMR) of the polysaccharide structure were performed. The NMR spectra were used to analyze the configuration and correlation of each bonding structure, and the configuration of Tremella fuciformis polysaccharide was mapped.

[0120] 5. Use commercially available kits to detect the levels of DAO, D-lactic acid, IL-10, and TNF-α in mouse serum.

[0121] Compared with the prior art, the present invention has the following beneficial technical effects:

[0122] 1. The present invention scientifically screens Tremella polysaccharides with a specific structure, which can prevent the shortening of the colon caused by colitis, reduce the activity of myeloperoxidase and serum diamine oxidase in the colon, and the concentration of D-lactic acid, and alleviate colon tissue damage; at the same time, it can activate Foxp3+T cells, promote the production of anti-inflammatory factors (IL-10, PPAR-γ), and reduce the production of pro-inflammatory factors (IFN-γ, IL-1β, IL-6, TGF-β and TNF-α) and intestinal immunoglobulin A (IgA). The Tremella polysaccharide of the present invention maintains the intestinal barrier by immunomodulation and restoration of intestinal microbial flora and microbial metabolism, as well as maintaining the integrity of intestinal cells, thereby achieving colitis prevention and treatment, and has the advantages of reducing the dosage used in colitis, reducing the total score of DAI, good effectiveness, high bioavailability, and good patient compliance, and has a good improvement effect on gastrointestinal dysfunction caused by digestive system diseases.

[0123] 2. The preparation method of the present invention has the advantages of simple operation, high yield, better cost, wide applicability to the population, and suitability for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0124] Figure 1 Study on the effect of Tremella fuciformis polysaccharide on colon cell integrity;

[0125] Figure 2 Study on the effect of Tremella fuciformis polysaccharide on the body weight of mice with colitis;

[0126] Figure 3 Study on the effect of Tremella fuciformis polysaccharide on the contents of DAO, D-lactic acid, IL-10 and TNF-α in the serum of colitis mice;

[0127] Figure 4 The invention relates to a study on the effect of the Tremella fuciformis polysaccharide on the disease activity index of colitis mice. DETAILED DESCRIPTION

[0128] The present invention will be described below with reference to Examples, but the present invention is not limited to these Examples.

[0129] The commercially available dried Tremella fuciformis in the specific embodiment was purchased from Sichuan Yudeyuan Ecological Agriculture Technology Co., Ltd., and the ion exchange column (DEAE Cellulose) was purchased from the United States. Gel chromatography columns (Superdex 75) were purchased from Cytiva (GE Life), human colon cancer Caco-2 cells were purchased, transwell culture plates were purchased from Corning, and palmitic acid was purchased from Sigma, Germany.

[0130] Example 1 Preparation of Tremella polysaccharide of the present invention

[0131] The preparation of Tremella polysaccharide comprises the following steps:

[0132] (1) 100 g of commercially available dried white fungus was crushed to 80 mesh, added with ddH2O at a mass volume ratio of 1:50 and soaked for 12 h, passed through a 100 mesh sieve, and obtained slag 1 and a sieved liquid. The sieved liquid was centrifuged (5000 g*10 min) to obtain slag 2 and a supernatant. Slag 1 and slag 2 were combined and then ddH2O was added at a mass volume ratio of 1:50 and soaked for 12 h, passed through a 100 mesh sieve, and slag 3 was collected.

[0133] (2) adding ddH2O to the residue 3 of step (1) at a mass volume ratio of 1:50, extracting at 90°C for 3h, centrifuging the extract (10000g*10min), collecting filtrate 1 and precipitate, adding ddH2O to the precipitate at a mass volume ratio of 1:50, extracting at 90°C for 3h, centrifuging the extract (10000g*10min), collecting filtrate 2, combining filtrate 1 and filtrate 2, adding 4 times the volume of anhydrous ethanol, and precipitating with alcohol for 12h until no precipitate is precipitated, and centrifuging the precipitate (10000g*10min) to obtain a solid phase and a liquid phase;

[0134] (3) adding 1% papain aqueous solution to the solid phase of step (2) at a mass-to-volume ratio of 1:50, and performing enzymatic hydrolysis at 60° C. for 12 h to obtain an enzymatic hydrolyzate;

[0135] (4) Add a chloroform / n-butanol mixed solution (the volume ratio of chloroform to n-butanol is 4:1) to the enzymatic hydrolyzate of step (3) in a 1:1 volume ratio, mix thoroughly, and centrifuge (1500 g*10 min), and collect the supernatant;

[0136] (5) Add 10% of the volume of petroleum ether to the supernatant of step (4), mix thoroughly, centrifuge (1500g*10min), collect the supernatant, add 4 times the volume of anhydrous ethanol, precipitate for 12h, centrifuge (1500g*10min), collect the precipitate, and obtain crude polysaccharide (5.97g);

[0137] (6) The crude polysaccharide obtained in step (5) was dissolved in pure water to prepare a 10 mg / mL crude polysaccharide mother liquor, and the mixture was centrifuged (10000 g*10 min). The supernatant was passed through a DEAE cellulose ion exchange column at a flow rate of 4 mL / min, and then eluted with pure water until the OD value of the polysaccharide content in the eluate was less than 0.05 (determined by sulfuric acid-phenol method). Then, the 0.1 M NaCl solution was replaced and eluted until the OD value of the polysaccharide content in the eluate was less than 0.05 (determined by sulfuric acid-phenol method). The 0.1 M NaCl eluate was collected, concentrated by rotary evaporation to 1 / 5 of the original volume, and dialyzed for 72 h using a 3000 Da dialysis bag to obtain purified polysaccharide (1.52 g).

[0138] (7) The polysaccharide purified in step (6) was added with pure water to prepare a 10 mg / mL polysaccharide mother liquor, and the mixture was centrifuged (10000 g*10 min). The supernatant was passed through a gel chromatography column at a flow rate of 1 mL / min, and eluted with 1.5 times the column volume of pure water. The eluate was collected and concentrated by rotary evaporation to 1 / 5 of the original volume to obtain Tremella polysaccharide (0.90 g).

[0139] Example 2 Preparation of Tremella polysaccharide of the present invention

[0140] The preparation of Tremella polysaccharide comprises the following steps:

[0141] (1) 100 g of commercially available dried white fungus was crushed to 80 mesh, added with ddH2O at a mass volume ratio of 1:80 and soaked for 12 h, passed through a 100 mesh sieve, and obtained slag 1 and a sieved liquid. The sieved liquid was centrifuged at 5000 g for 10 min to obtain slag 2 and a supernatant. Slag 1 and slag 2 were merged and then ddH2O was added to soak for 12 h, passed through a 100 mesh sieve, and slag 3 was collected.

[0142] (2) adding ddH2O to the residue 3 of step (1) at a mass volume ratio of 1:80, extracting at 90°C for 3h, centrifuging the extract (10000g*10min), collecting filtrate 1 and precipitate, adding ddH2O to the precipitate at a mass volume ratio of 1:80, extracting at 90°C for 3h, centrifuging the extract (10000g*10min), collecting filtrate 2, combining filtrate 1 and filtrate 2, adding 3 times the volume of anhydrous ethanol, and precipitating with alcohol for 12h until no precipitate is precipitated, and centrifuging the precipitate (10000g*10min) to obtain a solid phase and a liquid phase;

[0143] (3) adding 1% papain aqueous solution to the solid phase of step (2) at a mass-to-volume ratio of 1:60, and performing enzymatic hydrolysis at 60° C. for 12 h to obtain an enzymatic hydrolyzate;

[0144] (4) Add a chloroform / n-butanol mixed solution (the volume ratio of chloroform to n-butanol is 4:1) to the enzymatic hydrolyzate of step (3) in a 1:1 volume ratio, mix thoroughly, and centrifuge (1500 g*10 min), and collect the supernatant;

[0145] (5) Add 10% of the volume of petroleum ether to the supernatant of step (4), mix thoroughly, centrifuge (1500g*10min), collect the supernatant, add 3 times the volume of anhydrous ethanol, precipitate for 12h, centrifuge (1500g*10min), collect the precipitate, and obtain crude polysaccharide;

[0146] (6) The crude polysaccharide obtained in step (5) was dissolved in pure water to prepare a 10 mg / mL crude polysaccharide mother liquor, and the mixture was centrifuged (10,000 g for 10 min). The supernatant was passed through a DEAE cellulose ion exchange column at a flow rate of 4 mL / min, and then eluted with pure water until the OD value of the polysaccharide content in the eluate was less than 0.05 (determined by sulfuric acid-phenol method). The 0.1 M NaCl solution was then replaced and eluted until the OD value of the polysaccharide content in the eluate was less than 0.05 (determined by sulfuric acid-phenol method). The 0.1 M NaCl eluate was collected, concentrated by rotary evaporation to 1 / 5 of the original volume, and dialyzed for 72 h using a 3000 Da dialysis bag to obtain the purified polysaccharide.

[0147] (7) The polysaccharide purified in step (6) was added with pure water to prepare a 10 mg / mL polysaccharide mother liquor, and the mixture was centrifuged (10000 g*10 min). The supernatant was passed through a gel chromatography column at a flow rate of 1 mL / min, and eluted with 1.5 times the column volume of pure water. The eluate was collected and concentrated by rotary evaporation to 1 / 5 of the original volume to obtain Tremella polysaccharide (0.70 g).

[0148] Example 3 Preparation of Tremella polysaccharide of the present invention

[0149] The preparation of Tremella polysaccharide comprises the following steps:

[0150] (1) 100 g of commercially available dried white fungus was crushed to 80 mesh, added with ddH2O at a mass volume ratio of 1:100 and soaked for 24 h, passed through a 100 mesh sieve, and obtained slag 1 and sieved liquid. The sieved liquid was centrifuged at 5000 g for 10 min to obtain slag 2 and supernatant. Slag 1 and slag 2 were merged and then ddH2O was added to soak for 12 h, passed through a 100 mesh sieve, and slag 3 was collected.

[0151] (2) adding ddH2O to the residue 3 of step (1) at a mass volume ratio of 1:100, extracting at 70°C for 3h, centrifuging the extract (10000g*10min), collecting filtrate 1 and precipitate, adding ddH2O to the precipitate at a mass volume ratio of 1:100, extracting at 70°C for 3h, centrifuging the extract (10000g*10min), collecting filtrate 2, combining filtrate 1 and filtrate 2, adding 3 times the volume of anhydrous ethanol, and precipitating with alcohol for 12h until no precipitate is precipitated, and centrifuging the precipitate (10000g*10min) to obtain a solid phase and a liquid phase;

[0152] (3) adding 1% papain aqueous solution to the solid phase of step (2) at a mass-to-volume ratio of 1:60, and performing enzymatic hydrolysis at 60° C. for 24 h to obtain an enzymatic hydrolyzate;

[0153] (4) Add a chloroform / n-butanol mixed solution (the volume ratio of chloroform to n-butanol is 4:1) to the enzymatic hydrolyzate of step (3) in a 1:1 volume ratio, mix thoroughly, and centrifuge (1500 g*10 min), and collect the supernatant;

[0154] (5) Add 10% of the volume of petroleum ether to the supernatant of step (4), mix thoroughly, centrifuge (1500g*10min), collect the supernatant, add 4 times the volume of anhydrous ethanol, precipitate for 12h, centrifuge (1500g*10min), collect the precipitate, and obtain crude polysaccharide;

[0155] (6) The crude polysaccharide obtained in step (5) was dissolved in pure water to prepare a 10 mg / mL crude polysaccharide mother liquor, and the mixture was centrifuged (10,000 g for 10 min). The supernatant was passed through a DEAE cellulose ion exchange column at a flow rate of 4 mL / min, and then eluted with pure water until the OD value of the polysaccharide content in the eluate was less than 0.05 (determined by sulfuric acid-phenol method). The 0.1 M NaCl solution was then replaced and eluted until the OD value of the polysaccharide content in the eluate was less than 0.05 (determined by sulfuric acid-phenol method). The 0.1 M NaCl eluate was collected, concentrated by rotary evaporation to 1 / 5 of the original volume, and dialyzed for 72 h using a 3000 Da dialysis bag to obtain the purified polysaccharide.

[0156] (7) The polysaccharide purified in step (6) was added with pure water to prepare a 10 mg / mL polysaccharide mother liquor, and the mixture was centrifuged (10000 g*10 min). The supernatant was passed through a gel chromatography column at a flow rate of 1 mL / min, and eluted with 1.5 times the column volume of pure water. The eluate was collected and concentrated by rotary evaporation to 1 / 5 of the original volume to obtain Tremella polysaccharide (0.83 g).

[0157] Comparative Example 1 Preparation of Tremella polysaccharide

[0158] The preparation of Tremella polysaccharide comprises the following steps:

[0159] (1) 100 g of commercially available dried white fungus was crushed to 80 mesh, added with ddH2O at a mass volume ratio of 1:50 and soaked for 12 h, passed through a 100 mesh sieve, and obtained slag 1 and a sieved liquid. The sieved liquid was centrifuged (5000 g*10 min) to obtain slag 2 and a supernatant. Slag 1 and slag 2 were combined and then ddH2O was added at a mass volume ratio of 1:50 and soaked for 12 h, passed through a 100 mesh sieve, and slag 3 was collected.

[0160] (2) adding ddH2O to the residue 3 of step (1) at a mass volume ratio of 1:50, extracting at 90°C for 3h, centrifuging the extract (10000g*10min), collecting filtrate 1 and precipitate, adding ddH2O to the precipitate at a mass volume ratio of 1:50, extracting at 90°C for 3h, centrifuging the extract (10000g*10min), collecting filtrate 2, combining filtrate 1 and filtrate 2, adding 4 times the volume of anhydrous ethanol, and precipitating with alcohol for 12h until no precipitate is precipitated, and centrifuging the precipitate (10000g*10min) to obtain a solid phase and a liquid phase;

[0161] (3) adding 1% papain aqueous solution to the solid phase of step (2) at a mass-to-volume ratio of 1:50, and performing enzymatic hydrolysis at 60° C. for 12 h to obtain an enzymatic hydrolyzate;

[0162] (4) Add a chloroform / n-butanol mixed solution (the volume ratio of chloroform to n-butanol is 4:1) to the enzymatic hydrolyzate of step (3) in a 1:1 volume ratio, mix thoroughly, and centrifuge (1500 g*10 min), and collect the supernatant;

[0163] (5) Add 10% of the volume of petroleum ether to the supernatant of step (4), mix thoroughly, centrifuge (1500g*10min), collect the supernatant, add 4 times the volume of anhydrous ethanol, precipitate for 12h, centrifuge (1500g*10min), collect the precipitate, and obtain crude polysaccharide;

[0164] (6) The crude polysaccharide obtained in step (5) was dissolved in pure water to prepare a 10 mg / mL crude polysaccharide mother liquor, and the solution was centrifuged (10,000 g for 10 min). The supernatant was passed through a DEAE cellulose ion exchange column at a flow rate of 4 mL / min, and then eluted with pure water until the OD value of the polysaccharide content in the eluate was less than 0.05 (determined by the sulfuric acid-phenol method). The 0.1 M NaCl solution was then replaced and eluted until the OD value of the polysaccharide content in the eluate was less than 0.05 (determined by the sulfuric acid-phenol method). The 0.1 M NaCl eluate was collected, concentrated by rotary evaporation to 1 / 5 of the original volume, and dialyzed for 72 h using a 3000 Da dialysis bag to obtain the purified polysaccharide.

[0165] Test Example 1 Composition and structural characterization of Tremella polysaccharide of the present invention

[0166] According to the method of the present invention, the molecular weight Mn of the Tremella polysaccharide prepared in Example 1 is 4.535 (kDa), the polysaccharide structure is shown in Formula I, the polysaccharide content is 94.2%, and the distribution of each monosaccharide is: mannose 50.52%, glucuronic acid 23.12%, galactose 0.97%, xylose 11.95%, and fucose 13.44%.

[0167]

[0168] Test Example 2 Study on the effect of Tremella fuciformis polysaccharide on colon cell integrity

[0169] Human colon cancer Caco-2 cells were digested with 0.25% trypsin and seeded into transwell culture plates. DMEM culture medium was added to the upper and lower chambers of the transwell plates. The transwell plates were divided into four groups:

[0170] Blank group: Caco-2 cells were inoculated in the upper chamber to a cell concentration of 1×10 5 / mL;

[0171] Model group: Caco-2 cells were inoculated in the upper chamber to a cell concentration of 1×10 5 / mL, and 400μM palmitic acid was added at the same time;

[0172] Experimental group: Caco-2 cells were inoculated in the upper chamber to a cell concentration of 1×10 5 / mL, and palmitic acid and Tremella polysaccharide of Example 1 were added simultaneously to make the final concentration of palmitic acid 400 μM and the final concentration of Tremella polysaccharide 400 μg / mL;

[0173] Control group: Caco-2 cells were inoculated in the upper chamber to a cell concentration of 1×10 5 / mL, and palmitic acid and the Tremella polysaccharide of Example 1 were added at the same time to make the final concentration of palmitic acid 400 μM and the final concentration of Tremella polysaccharide 400 μg / mL.

[0174] Each group was cultured in a 37°C, 5% CO2 incubator. DMEM medium was replaced every other day for the first week. Starting from the second week, the medium was changed daily until day 21. TEER values were measured using an electrical resistance meter to monitor cell monolayer integrity. TEER values were calculated using the following formula (using a 24-well transwell plate with a membrane area of 0.33 cm). 2 ):

[0175] TEER / (Ω·cm 2 )=[TEER 样品孔 (Ω)-TEER 空白组孔 (Ω)]×area(cm 2 ),Knot

[0176] Fruit Figure 1 Compared with the blank group, the model group had a significant decrease (**p<0.01); compared with the model group, the experimental group had a significant increase (##p<0.01).

[0177] Test Example 3 Study on the effect of Tremella fuciformis polysaccharide on colitis mice

[0178] Forty healthy C57 male mice aged 8 weeks and weighing 18-20 g were selected and randomly divided into four groups of 10 mice each after being acclimated to a constant temperature of 25°C for one week: normal group, model group (dextran sulfate sodium induced colitis group), experimental group, and control group. The mice in each group drank distilled water normally every day.

[0179] Normal group: no drugs were administered orally from day 1 to day 14;

[0180] Model group: No drugs were given orally from day 1 to day 7, and 3% dextran sulfate sodium solution was freely available for drinking from day 8 to day 14.

[0181] Experimental group: 200 mg / kg of Tremella fuciformis polysaccharide of Example 1 was administered orally daily from day 1 to day 14, and 3% dextran sulfate sodium solution was freely consumed daily from day 8 to day 14;

[0182] Control group: 200 mg / kg of Tremella fuciformis polysaccharide of Comparative Example 1 was orally administered daily from day 1 to day 14, and 3% dextran sulfate sodium solution was freely drunk daily from day 8 to day 14.

[0183] On day 14, the activity of the mice was observed 1 hour after the last administration and the mice were killed 8 hours later.

[0184] From day 8 to day 14, the following indicators were recorded at a fixed time every day (9:00 AM): weight change (accurately weigh each mouse to calculate the percentage change relative to the initial weight), stool characteristics (formed, loose, watery stools), and blood in stools.

[0185] The results of mouse weight changes are shown in Figure 2 The model group showed a significant decrease compared with the normal group (**p<0.01), and the experimental group and the control group showed a significant increase compared with the model group (#p<0.05).

[0186] The levels of DAO, D-lactic acid, IL-10, and TNF-α in mouse serum were detected by ELISA kits. Figure 3 The model group showed significant differences compared with the normal group (*p<0.05, **p<0.01), and the experimental group showed significant improvement compared with the model group (##p<0.01).

[0187] The disease activity index (DAI) of colitis mice was calculated according to the scoring criteria in Table 1. The total DAI score = weight change score + fecal characteristics score + blood in stool score. Figure 4 Compared with the control group, the experimental group significantly improved the symptoms of colitis.

[0188] Table 1

[0189]

[0190] The above embodiments are only intended to help understand the method and core concept of the present invention. It should be noted that, without departing from the principles of the present invention, a number of improvements and modifications may be made to the present invention by those skilled in the art, and such improvements and modifications also fall within the scope of protection of the claims of the present invention.

Claims

1. A Tremella polysaccharide having the effect of preventing and treating colitis, having a structure of formula I, 2. Tremella polysaccharide as claimed in claim 1, in the structure of formula I, the main chain structure is formed by repeated (3)-α-D-mannose-(1→) and (2,3)-α-D-6-methoxyglucuronic acid-(1→) units connected to each other; branch one is composed of β-D-glucuronic acid-(1→); branch two is composed of α-L-fucose connected to β-D-xylose-(1→) by a (1→2) bond; the branch is connected to the main chain by the O-2 position of the sugar residue (2,3)-α-D-6-methoxyglucuronic acid-(1→) in the main chain; n represents the number of glycosyl groups connected in the sugar chain, and n is greater than 10.

3. The Tremella polysaccharide according to any one of claims 1 to 2, wherein the number average molecular weight of the Tremella polysaccharide is 1 kDa-250 kDa, preferably 1 kDa-100 kDa, more preferably 1 kDa-50 kDa, and even more preferably 1 kDa-10 kDa.

4. The Tremella polysaccharide according to any one of claims 1 to 3, wherein the polysaccharide content in the Tremella polysaccharide is not less than 80%, preferably not less than 90%.

5. The Tremella polysaccharide according to any one of claims 1 to 4, wherein the monosaccharide distribution in the Tremella polysaccharide is 40-60% mannose, 20-30% glucose, 0.1-10% galactose, 10-20% xylose, and 10-20% fucose.

6. The method for preparing Tremella polysaccharide according to any one of claims 1 to 5, comprising the following steps: (1) soaking Tremella fuciformis in water and sieving it, centrifuging the sieved liquid, and collecting the residue; (2) Add water to the residue of step (1) to extract, collect the filtrate, add ethyl acetate to the filtrate, Alcohol, alcohol precipitation to collect the solid phase; (3) adding protease to the solid phase of step (2) for enzymatic hydrolysis, and collecting the enzymatic hydrolysis solution; (4) Add chloroform / n-butanol to the enzymatic hydrolyzate of step (3), mix well, and centrifuge. Collect the supernatant; (5) adding petroleum ether to the supernatant of step (4), mixing, centrifuging, and collecting the supernatant; then adding ethanol, precipitating with alcohol, centrifuging, and collecting the precipitate to obtain crude polysaccharide; (6) dissolving the crude polysaccharide in step (5) in water, centrifuging, taking the supernatant, and purifying it through an ion exchange column; The eluate is collected, concentrated, and desalted to obtain the purified polysaccharide; (7) The polysaccharide purified in step (6) is dissolved in water, centrifuged, the supernatant is collected, and the supernatant is separated and purified by gel chromatography column, and the eluate is collected and concentrated to obtain Tremella polysaccharide.

7. The method according to claim 6, wherein in step (6), the ion exchange column filler is selected from any one of DEAE cellulose, DEAE dextran, and DEAE agarose, or a combination thereof.

8. The method according to any one of claims 6 to 7, wherein in step (7), the gel chromatography column filler is any one of Superdex75, Superdex200, Superdex30, or a combination thereof.

9. A pharmaceutical composition, comprising the Tremella polysaccharide according to any one of claims 1 to 5 or the Tremella polysaccharide prepared by the method according to any one of claims 6 to 8 and a pharmaceutically acceptable carrier.

10. Use of the Tremella polysaccharide according to any one of claims 1 to 5, the Tremella polysaccharide obtained by the method according to any one of claims 6 to 8, or the pharmaceutical composition according to claim 9 in preparing products for preventing and treating colitis, regulating intestinal flora, enhancing immunity, and improving gastrointestinal dysfunction.